3D modeling of dengue virus NS4B and Chikungunya virus nsP4: Identification of a common drug target and designing a single antiviral inhibitor

Current Computer-Aided Drug Design

Volumn 10, Issue 4, 2014, Pages 361-373

  Satheesh, Garisekurthi ^a   Prabhu, Nagu P ^a   Venkataramana, Musturi ^a  

^a UNIVERSITY OF HYDERABAD   (India)

Author keywords

3D modeling; Chikungunya virus; Dengue virus; MD simulations; Molecular docking; NS4B; nsP4. Flavivirdae; Togaviridae

Indexed keywords

ANTIVIRAL AGENTS; MOLECULES; PROTEINS;

3D MODELS; 3D-MODELING; CHIKUNGUNYA; CHIKUNGUNYA VIRUS; DENGUE VIRUS; FLAVIVIRDAE; MD SIMULATION; MOLECULAR DOCKING; NON-STRUCTURAL; NON-STRUCTURAL PROTEIN-4B; NON-STRUCTURAL PROTEIN-P4.; STRUCTURAL PROTEINS; TOGAVIRIDA;

VIRUSES;

ANTIVIRUS AGENT; NONSTRUCTURAL PROTEIN 4B; NONSTRUCTURAL PROTEIN P4; UNCLASSIFIED DRUG; BENZAMIDE DERIVATIVE; PYRIDINE DERIVATIVE; VIRUS PROTEIN;

AB INITIO CALCULATION; ALGORITHM; ALPHA HELIX; AMINO ACID SEQUENCE; ARTICLE; BINDING KINETICS; BIOINFORMATICS; CHIKUNGUNYA; CHIKUNGUNYA VIRUS; DENGUE; DENGUE VIRUS; DRUG DESIGN; DRUG SCREENING; DRUG TARGETING; HUMAN; MATHEMATICAL MODEL; MIXED INFECTION; MOLECULAR DOCKING; MOLECULAR DYNAMICS; MOSQUITO; NONHUMAN; NUCLEOTIDE SEQUENCE; PHYLOGENY; PROTEIN STRUCTURE; SEQUENCE ALIGNMENT; SEQUENCE ANALYSIS; STRUCTURAL HOMOLOGY; VIRUS TRANSMISSION; ANTAGONISTS AND INHIBITORS; BINDING SITE; CHEMICAL STRUCTURE; CHEMISTRY;

ANTIVIRAL AGENTS; BENZAMIDES; BINDING SITES; CHIKUNGUNYA VIRUS; DENGUE VIRUS; DRUG DESIGN; MODELS, MOLECULAR; PYRIDINES; VIRAL NONSTRUCTURAL PROTEINS;

EID: 84946899894     PISSN: 15734099     EISSN: 18756697     Source Type: Journal    
DOI: 10.2174/1573409911666150407161535     Document Type: Article

References (102)

1. Sudeep, A.B.; Parashar, D. Chikungunya: an overview. J. Biosci., 2008, 33, 443-449.
2. Venkataramana, M.; Vindal, V.; Kondapi, A.K. Emergence of swine flu in Andhra Pradesh: Facts and future. Indian J. Microbiol., 2009, 49, 320-323.
3. Sayce, A.C.; Miller, J.L.; Zitzmann N. Targeting a host process as an antiviral approach against dengue virus. Trends Microbiol., 2010, 18, 323-330.
4. Guzman, M.G.; Halstead, S.B.; Artsob, H.; Buchy, P.; Farrar, J.; Gubler, D.J.; Hunsperger, E.; Kroeger, A.; Margolis, H.S.; Martínez, H.; Nathan, M.B.; Pelegrino, J.L.; Simmons, C.; Yoksan, S.; Peeling, R.W. Dengue: a continuing global threat. Nat. Rev. Microbiol., 2010, 8(12 Suppl), S7-S16.
5. Murray, N.E.A.; Quam, M.B.; Smith, A.W. Epidemiology of dengue: past, present, and future prospects. Clin. Epidemiol., 2013, 5, 299-309.
6. Buonsenso, D.; Barone, G.; Onesimo, R.; Calzedda, R.; Chiaretti, A.; Valentini, P. The re-emergence of dengue virus in non-endemic countries: a case series. BMC Research Notes., 2014, 9, 596.
7. Daep, C.A.; Munoz-Jordan, J.L.; Eugenin, E.A. Flaviviruses, an expanding threat in public health: focus on dengue, West Nile, and Japanese encephalitis virus. J. Neurovirol., 2014, 20(6), 539-560.
8. Laharia, C.; Pradhan, S.K. Emergence of chikungunya virus in Indian subcontinent after 32 years. J. Vect. Borne. Dis., 2006, 43, 151-160.
9. Solignat, M.; Gay, B.; Higgs, S.; Briant, L.; Devaux, C. Replication cycle of Chikungunya virus: A re-emerging arbovirus. Virology, 2006, 393, 183-197.
10. Volk, S.M.; Chen, R.; Tsetsarkin, K.A.; Adams, A.P.; Garcia, T.I.; Sall, A.A.; Nasar, F.; Schuh, A.J.; Holmes, E.C.; Higgs, S.; Maharaj, P.D.; Brault, A.C.; Weaver, S.C. Genome scale phylogenetic analysis of chikungunya virus reveal independent emergences of recent epidemics and various evolutionary rate. J. Virol., 2010, 84, 6497-6504.
11. Taraphdar, D.; Sarkar, A.; Mukhopadhyay, B.B.; Chakrabarti, S; Chatterjee, S. Rapid spread of Chikungunya virus following its resurgence during 2006 in West Bengal, India. Trans. R. Soc. Trop. Med. Hyg. 2012, 106(3), 160-166.
12. Caglioti, C.; Lalle, E.; Castlletti, C.; Carletti, F.; Capobianchi, M.R.; Bordi, L. Chikungunya virus infection: an overview. New Microbiologica., 2013, 36, 211-227.
13. Afreen, M.; Deeba, F.; Khan, W.H.; Haider, S.H.; Kazim, S.N.; Ishrat, R.; Naqui, I.H.; Shareef, M.Y.; Broor, S.; Ahmed, A.; Parveen, S. Molecular characterization of dengue and Chikungunya virus strains circulating in New Delhi, India. Microbial Immunol., 2014, 58(12), 688-696.
14. Vijayakumar, T.S.; Chandy, S.; Sathish, N.; Abraham, M.; Abraham, P.; Sridharan, S.; Is dengue emerging as a major public health problem? Indian J. Med. Res., 2005, 121, 100-107
15. Gupta, K.; dar, L.; Kapoor, G.; Broor, S. The changing epidemiology of Dengue in Delhi, India. Virol. J., 2006, 3, 92.
16. Paramasivan, R.; Dhananjeyan, K.J.; Leo, S.V.J.; Muniaraj, M.; Thenmozhi, V.; Rajendran, R.; Tewari, S.C.; Arunachalam, N.; Varatharaj, M.; victor, T.J.; Charles, J.; Ilango, S.; Tyagi, B.K. Dengue fever caused by dengue virus serotype-3 (subtype-III) in a rural area of Madurai district, Tamil Nadu. Indian J. Med. Res., 2010, 132, 339-342.
17. Dash, P.K.; Sharma, S.; Srivastava, T.; Santhosh, S.R.; Parida, M.M.; Neeraja, M.; Subbalakshmi, M.V.S.; Lakshmi, V.; Rao, P.V.L. Emergence of dengue virus type 4 (genotype 1) in India. Epidemiol Infect., 2010, 1-5.
18. Chakravarti, A.; Kumar, A.; Matlani, M. Displacement of dengue virus type 3 and type 2 by dengue virus type 1 in Delhi during 2008. Indian J. Med. Microbiol., 2010, 28, 412-418.
19. Dash, P.K.; Sharma, S.; Soni, M.; Agarwal, A.; Sahni, A.K.; Parida, M. Complete genome sequencing and evolutionary phylogeography analysis of Indian Isolates of Dengue virus Type 1. Virus Res., 2015, 195, 124-134.
20. Shrinet, J.; Jain, S.; Sharma, A.; Singh, S.S.; Mathu, K.; Rana, V.; Bhatnagar, R.K.; Gupta, B.; Gaind, R.; Deb, M.; Sunil, S. Genetic characterization of Chikungunya virus from New Delhi reveal emergence of a new molecular signature in Indian Isolates. Virol. J., 2012, 9, 100.
21. Billoir, F.; de Chesse, R.; Tolou, H.; de Micco, P.; Gould, E.A.; de Lamballerie, X. Phylogeny of the genus Flavivirus using complete coding sequences of antropod-borne viruses and viruses with no known vector. J. Gen. Virol., 2000, 81, 781-790.
22. Weaver, S.C.; Vasilakis, N. Molecular evolution of dengue viruses: Contributions of phylogenetics to understanding the history and epidemiology of preeminent arboviral disease. Infect. Genet. Evol., 2009, 9, 523-540.
23. Holmes, E.C.; Twiddy, S.S. The origin, emergence, and evolutionary genetics of dengue virus. Infect. Genet. Evol., 2003, 3, 19-28.
24. Robinson, M.C. An epidemic of virus disease in Southern Province Tanganyika Territory in 1945. Trans. R. Soc. Trop. Med. Hyg., 1955, 49, 28-32.
25. Chaturvedi, U.C.; Nagar, R. Dengue and dengue haemorrhagic fever: Indian perspective. J. Biosci., 2008, 33, 429-441.
26. Pang, X.; Zhang, M.; Dayton, A.I. Development of dengue virus 2 replicons capable of prolonged expression in host cells. BMC Microbiol., 2001, 1, 18.
27. Myers, R.M.; Cary, D.E. Concurrent isolation from patients of two arboviruses: chikungunya and dengue virus type 2. Science, 1967, 157, 1307-1308.
28. Mackenzie, J.S.; Chua, K.B.; Daniels, P.W.; Eaton, B.T.; Field, H.E.; Hall, R.A.; Halpin, K.; Johansen, C.A.; Kirkland, P.D.; Lam, S.K.; McMinn, P.; Nisbet, D.J.; Paru, R.; Pyke, A.T.; Ritchie, S.A.; Siba, P.; Smith, D.W.; Smith, G.A.; van den Hurk, A.F.; Wang, L.F.; Williams, D.T. Emerging viral diseases of Southeast Asia and the Western Pacific. Emerg. Infect. Dis., 2001, 7, 497-504.
29. Chang, S.F.; Su, C.L.; Shu, P.; Yang, C.F.; Liao, T.L.; Cheng, C.H.; Hu, H.C.; Huang, J.H. Concurrent isolation of chikungunya virus and dengue virus from a patient with co-infection resulting from a trip to Singapore. J. Clin. Microbiol., 2010, 48, 4586-4589.
30. Nayar, S.K.; Noridah, O.; Paranthaman, V.; Ranjit, K.; Norizah, I.; Chem, Y.K.; Mustafa, B.; Chua, K.B. Co-infection of dengue virus and chikungunya virus in two patients with acute febrile illness. Med. J. Malaysia, 2007, 62, 335-336.
31. Leroy, E.M.; Nokoghe, D.; Ollomo, B.; Nze-Nkogue, C.; Becquart, P.; Grard, G.; Pourrut, X.; Charrel, R.; Moureau, G.; Ndjoyi-Mbiguino, A.; De Lamballerie, X. Concurrent chikungunya and dengue virus infections during simultaneous outbreaks. Gabon 2007. Emerg. Infect. Dis., 2007, 15, 591-593.
32. Hapuarachechchi, H.A.; Bandara, K.B.; Hapugoda, M.D.; Williams, S.; Abeyewickreme, W. Laboratory confirmation of dengue and chikungunya co-infection. Ceylon. Med. J., 2008, 53, 104-105.
33. Chahar S.H.; Bharaj P.; Dar L.; Guleria R.; Kabra S.K.; Shoba B. Co-infections with chikungunya virus and dengue virus in Delhi.; India. Emeg. Infect. Dis., 2009, 15, 1077-1080.
34. Baba, M.; Logue, C.H.; Oderinde, B.; Adbulmaleek, H.; Williams, J.; Lewis, J.; Laws, T.R.; Hewson, R.; Marcello, A.; D’Agaro, P. Evidence of arbovirus co-infections in suspected febrile malaria and typhoid patients in Nigeria. J. Infect. Dev. Ctries., 2013, 7, 051-059.
35. Carey, D.E. Chikungunya and dengue: A case of mistake identity? J. Hist. Med. Allied. Sci., 1971, 26, 243-262.
36. Whitehead, S.S.; Falgout, B.; Hanley, K.A.; Blaney Jr, J.E.; Markoff, L.; Murphy, B.R. A live attenuated dengue virus type 1 vaccine candidate with a 30-nucleotide deletion in the 3’ untranslated region is highly attenuated and immunogenic in monkeys. J. Virol., 2003, 77, 1653-1657.
37. Akahata, W.; Yang, Z.Y.; Andersen, H.; Sun, S.; Holdaway, H.A.; Kong, W.P.; Lewis, M.G.; Higgs, S.; Rossmann, M.G.; Rao, S.; Nabel, G.J. A virus like particle vaccine for epidemic Chikungunya virus protects nonhuman primates against infection. Nat. Med., 2010, 16, 334-338.
38. Wichapong, K.; Nueangaudom, A.; Pianwanit, S.; Sippl, W.; Kokpol, S. Identification of potential hit compounds for Dengue virus NS2B/NS3 protease inhibitors by combining virtual screening and binding free energy calculations. Trop. Biomed., 2013, 30, 388-403.
39. Wan, S.-W.; Lin, C.-F.; Wang, S.; Chen, Y.-H.; Yeh, T.-M.; Liu, H.-S.; Anderson, R.; Lin, Y.-S. Current progress in dengue vaccines. J. Biomed. Sci., 2013, 20, 37.
40. Chattopadhyay, S.; Kumar, A.; Mamidi, P.; Nayak, T.K.; Das, I.; Chhatai, J.; Basantray, I.; Bramha, U.; Maiti, P.K.; Singh, S.; Suryawanshi, A.R.; Chattopadhyay, S. Development and characterization of monoclonal antibody against non-structural protein-2 of Chikungunya virus and its application. J. Virol. Methods., 2014, 199, 86-94.
41. Rodriguez-Barraquer, I.; Mier-y-Teran-Romero, L.; Schwartz, I.B.; Burke, D.S.; Cummings, D.A.T. Potential opportunities and perils of imperfect dengue vaccines. Vaccine, 2014, 32, 514-520.
42. Rashad, A.A.; Mahalingam, S.; Keller, P.A. Chikungunya Virus: Emerging targets and new opportunities for medicinal Chemistry. J. Med. Chem., 2014, 57, 1147-1166.
43. Khalil, S.M.; Tonkin, D.R.; Mattocks, M.D.; Snead, A.T.; Johnston, R.E.; White, L.J. A tetravalent alphavirus-vector based dengue vaccine provides effective immunity in an early life mouse model. Vaccine, 2014, 32, 4068-4074.
44. Mola, A.D.; Peduto, A.; Gatta, A.L.; Delang, L.; Pastorino, B.; Neyts, J.; Leyssen, P.; de Rosa, M.; Filosa, R. Structure-activity relationship study of arbidol derivatives as inhibitors of chikungunya virus replication. Bioorg. Med. Chem., 2014, 22, 6014-6025.
45. Parashar, D.; Cherian, S. Antiviral perspectives for chikungunya Virus. Biomed. Res. Int., 2014, 2014, 631642.
46. Khanam, S.; Pilankatta, R.; Khanna, N.; Swaminathan, S. An adenovirus type 5 (Adv5) vector encoding an envelop domain III based tetravalent antigen elicits immune responses against all four dengue viruses in the presence of prior Adv5 immunity. Vaccine, 2009, 27, 6011-6021.
47. Zust, R.; Dong, H.; Li X.-F.; Chang, D.C.; Zhang, B.; Balakrishnan, T.; Toh Y.-X.; Jiang, T.; Li, S.-H.; Deng, Y.-Q.; Ellis, B.R.; Ellis, E.M.; Poidinger, M.; Zolezzi, F.; Qin, C.-F.; Shi, P.Y.; Fink, K. Rational design of a live attenuated dengue vaccine: 2’- O-Methyltransferase Mutants are highly attenuated and immunogenic in mice and macaques. PLoS Pathog., 2013, 9, e1003521.
48. Tamura, K.; Dudley, J.; Nei, M.; Kumar, S. MEGA4: Molecular Evolutionary Genetics Analysis (MEGA) software version 4.0. Mol. Biol. Evol., 2007, 24, 1596-1599.
49. Zhang, Y. I-TASSER server for protein 3D structure prediction. BMC Bioinformatics., 2008, 9, 40.
50. Roy, A.; Kucukural, A.; Zhang, Y. I-TASSER: a unified platform for automated protein structure and function prediction. Nat. Protoc., 2010, 5, 725-738.
51. Ramachandran, G.N.; Ramakrishnan, C.; Sasisekharan, V. Stereochemistry of polypeptide chain configurations. J. Mol. Biol., 1963, 7, 95-99.
52. Laskowski, R.A.; MacArthur, M.W.; Moss, D.S.; Thornton, J.M. PROCHECK - a program to check the stereochemical quality of protein structures. J. App. Cryst., 1993, 26, 283-291.
53. Hooft, R.W.W.; Vriend, G.; Sander, C.; Abola, E.E. Errors in protein structures. Nature, 1996, 381, 272.
54. Pettersen, E.F.; Goddard, T.D.; Huang, C.C.; Couch, G.S.; Greenblatt, D.M.; Meng, E.C.; Ferrin, T.E. UCSF Chimera – a visualization system for exploratory research and analysis. J. Comput. Chem., 2004, 25, 1605-1612.
55. Trott, O.; Olson, A.J. AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization and multithreading. J. Comput. Chem., 2010, 31, 455-461.
56. Tripos Inc. Sybyl 1.1. St. Louis, MO.; 2001.
57. O'Boyle, N.M.; Banck, M.; James, C.A.; Morley, C.; Vandermeersch, T.; Hutchison, G.R. Open Babel: An open chemical toolbox. J. Cheminform., 2011, 3, 33.
58. Morris, G.M.; Huey, R.; Lindstrom, W.; Sanner, M.F.; Belew, R.K.; Goodsell, A.S.; Olson, A.J. Autodock4 and AutoDockTools4: Automated docking with selective receptor flexiblity. J. Comput. Chem., 2009, 30, 2785-2791.
59. Jones, G.; Willett, P.; Glen, R.C. Molecular recognition of receptor sites using a genetic algorithm with a description of desolvation. J. Mol. Biol., 1995, 245, 43-53.
60. Jones, G.; Willett, P.; Glen, R.C.; Leach, A.R.; Taylor, R. Development and validation of a genetic algorithm for flexible docking. J. Mol. Biol., 1997, 267, 727-748.
61. Verdonk, M.L.; Cole, J.C.; Hartshorn, M.J.; Murray, C.W.; Taylor, R.D. Improved protein-ligand docking using GOLD. Proteins, 2003, 52, 609-623.
62. Berendsen, H.J.C.; van der Spoel, D.; van Drunen, R. GROMACS: A message passing parallel molecular dynamics implementation. Comput. Phys. Commun., 1995, 91, 43-56.
63. Oostenbrink, C.; Villa, A.; Mark, A.E.; Van Gunsteren, W.F. A biomolecular force field based on the free enthalpy of hydration and solvation: The GROMOS force-field parameter sets 53A5 and 53A6. J. Comput. Chem., 2004, 25, 1656-1676.
64. Malde, A.K.; Zuo, L.; Breeze, M.; Stroet, M.; Poger, D.; Nair, P.C.; Oostenbrink, C.; Mark, A.E. An Automated force field Topology Builder (ATB) and repository: version 1.0. J. Chem. Theory. Comput., 2011, 7, 4026-4037.
65. Parrinello, M.; Rahman, A. Polymorphic transitions in single crystals: A new molecular dynamics method. J. Appl. Phys., 1981, 52, 7182-7190.
66. Essmann, U.; Perera, L.; Berkowitz, M.; Darden, T.; Lee, H.; Pedersen, L. A smooth particle mesh Ewald method. J. Chem. Phys., 1995, 103, 8577-8593.
67. Lin, J.H.; Perryman, A.L.; Schames, J.R.; McCammon, J.A. Computational drug design accommodating receptor flexibility: The relaxed complex scheme. J. Am. Chem. Soc., 2002, 124, 5632-5633.
68. Srinivasan, J.; Cheatham, P.; Cieplak, T.E.; Kollman, P.A.; Case, D.A. Continuum solvent studies of the stability of DNA, RNA, and phosphoramidate−DNA helices. J. Am. Chem. Soc., 1998, 120, 9401-9409.
69. Kumari, R.; Kumar, R.; Drug Discovery Consortium, O.P.; Lynn, A. g_mmpbsa - A GROMACS tool for high-throughput MM-PBSA calculations. J. Chem. Inf. Model., 2014, 54, 1951-1962.
70. Shipman, C.; Smith, S.H.; Drach, J.C.; Klayman, D. Antiviral activity of 2-acetylpyridine thiosemicarbazones aganist herpes simplex virus. Antimicrob. Agents Chemother., 1981, 19, 682-685.
71. Turk, S.R.; Shipman, C.; Drach, J.C. Structure activity relationships among α-(N)-Heterocyclic acyl thiosemicarbazones and related compounds as inhibitors of herpes simplex virus type 1-specified ribonucleoside diphosphate reductase. J. Gen. Virol., 1986, 67, 1625-1632.
72. Kempf, D.J.; Marsh, K.C.; Denissen, J.F.; Mcdonald, E.; Vasavanonda, S.; Flentge, C.A.; Green, B.E.; Fino, L.; Parks, C.H.; Kong, X.P.; Widebur, N.E.; Saldivar, A.; Ruiz, L.; Kati, W.M.; Sham, H.L.; Robins, T.; Stewarti, K.D.; Hsu, A.; Plattner, J.J.; Leonard, J.M.; Norbeck, D.W. ABT-538 is a potent inhibition of human immunodeficiency virus protease and has high oral bioavailability in humans. Proc. Natl. Acad. Sci. USA, 1995, 92, 2484-2488.
73. Muthukumaran, J.; Karthikeyan, S.; Satheesh, G.; Manimaran, B.; Krishna, R. Butane-1.;4-diyl bis (pyridine-4-carboxylate). Acta Cryst., 2011, E67, o1803.
74. Singh, Kh.D.; Kirubakaran, P.; Nagarajan, S.; Sakkiah, S.; Muthuswamy, K.; Velmurugan, D.; Jeyakanthan, J. Homology modelling, molecular dynamics, e-pharmacophore mapping and docking study of chikungunya virus of nsP2 protease. J. Mol. Model., 2012, 18, 39-51.
75. Chao, B.; Tong, X.K.; Tang, W.; Li, D.W.; He, P.L.; Garcia, J.M.; Zeng, L.M.; Gao, A.H.; Yang, L.; Li, J.; Nan, F.J.; Jacobs, M.; Altmeyer, R.; Zuo, J.P.; Hu, Y.H. Discovery and optimization of 2.;4 Diaminoquinazoline derivatives as a new class of potent dengue virus inhibitors. J. Med. Chem., 2012, 55, 3135-3143.
76. Breen, R.A.M.; Swaden, L.; Ballinger, J.; Lipman, M.C.I. Tuberculosis and HIV co-Infection: a practical therapeutic approach. Drugs, 2006, 66, 2299-2308.
77. Regazzi, M.; Carvalho, A.C.; Villani, P.; Matteelli, A. Treatment optimization in patients co-infected with HIV and Mycobacterium tuberculosis infections: Focus on drug-drug interactions with Rifamycines. Clin. Pharmacokinet., 2014, 1179-1926.
78. Kalwat, U.; Sharma, K.K.; Reddy, S.G. Prevalence of dengue and chikungunya fever and their coinfection. Indian J. Pathol. Microbiol., 2011, 54, 844-846.
79. Saha, K.; Firdaus, R.; Chakrabarti, S.; Sadhukhan, P.C. Development of rapid, sensitive one-tube duplex RT-PCR assay for specific and differential diagnosis of Chikungunya and dengue. J. Virol. Meth., 2013, 193, 521-524.
80. Olagnier, D.; Scholte, F.E.M.; Chiang, C.; Albulescu, I.C.; Nichols, C.; He, Z.; Lin, R.; Snijder, J.; van Hemert, M.J.; Hiscott, J. Inhibition of dengue and chikungunya virus infections by RIG-Imediated type I interferon-independent stimulation of the innate antiviral response. J. Virol., 2014, 88, 4180.
81. Khan, A.M.; Miotto, O.; Heiny, A.T.; Salmon, J.; Srinivasan, K.N.; Nascimento, E.J.M.; Marques Jr., E.T.A.; Brusic, V.; Tan, T.W.; August, J.M. A Systematic bioinformatics approach for selection of epitope-based vaccine targets. Cell Immunol., 2006, 244, 141-147.
82. Powers, A.M.; Brault, A.C.; Tesh, R.B.; Weaver, S.C. Reemergence of chikungunya and o’nyong-nyong viruses: evidence for distinct geographical lineages and distant evolutionary relationships. J. Gen. Virol., 2000, 81, 471-479.
83. Rodpothong, P.; Auewarakul P. Positive selection sites in the surface genes of dengue virus: phylogenetic analysis of the interserotypic branches of the four serotypes. Virus Genes, 2012, 44, 408-414.
84. Dash, P.K.; Sharma, S.; Soni, M.; Agarwal, A.; Parida, M.; Rao, P.V.L. Complete genome sequencing and evolutionary analysis of Indian isolates of Dengue virus type 2. Biochem. Biophys. Res. Commun., 2013, 436, 478-485.
85. Wichapong K.; Pianwanit S.; Sippl W.; Kokpol S. Homology modeling and molecular dynamics simulations of Dengue virus NS2B/NS3 protease: insight into molecular interaction. J. Mol. Recognit., 2009, 23, 283-300.
86. Yu, H.; Fang, Y.; Lu, X.; Liu, Y.; Zhang, H. Combined 3D-QSAR, molecular docking, molecular dynamics simulation, and binding free energy calculation studies on the 5-Hydroxy-2H-Pyridazin-3-one derivatives as HCV NS5B polymerase inhibitors. Chem. Biol. Drug Des., 2014, 83, 89-105.
87. Venkatramana, M.; Ray, P.S.; Chadda, A.; Das, S. A 25 kDa cleavage product of Polypyrimidine tract binding protein (PTB) present in mouse tissues prevents PTB binding to the 5’ untranslated region and inhibits translation of Hepatitis A virus RNA. Virus Res., 2003, 98, 141-149.
88. Bhakat, S.; Karubiu, W.; Jayaprakash, V.; Soliman, M.E.S. A perspective on targeting non-structural proteins to combat neglected tropical diseases: Dengue, West Nile and Chikungunya viruses. Eur. J. Med. Chem., 2014, 87, 677-702.
89. Welsch, C.; Albrecht, M.; Maydt, J.; Herrmann, E.; Welker, M.W.; Sarrazin, C.; Scheidig, A.; Lengauer, T.; Zeuzem, S. Structural and functional comparison of the non-structural protein 4B in flaviviridae. J. Mol. Graph. Model., 2007, 26, 546-557.
90. Palomares-Jerez, F.; Nemesio, H.; Villalaín, J. The membrane spanning domains of protein NS4B from hepatitis C virus. Biochim. Biophys. Acta, 2012, 1818, 2958-2966.
91. Munoz-Jordan, J.L.; Sanchez-Burgos, G.G.; Laurent-Rolle, L.; Gareia-Sastre, A. Inhibition of interferons signaling by dengue virus. Proc. Natl. Acad. Sci. USA, 2003, 100, 14333-14338.
92. Munoz-Jordan, J.L.; Laurent-Rolle, L.; Ashour, J.; Martinez-Sohrido, L.; Ashok, M.; lan Lipkin, W.; Gareia-Sastre A. Inhibition of Alpha/Beta interferon signaling by the NS4B protein of Flaviviruses. J. Virol., 2005, 79, 8004-8013.
93. Xie, X.; Wang, Q.-Y.; Xu, H.Y.; Qing, M.; Kramer, L.; Yuan, Z.; Shi, P.-Y. Inhibition of dengue virus by targeting viral NS4B protein. J. Virol., 2011, 85, 11183-11195.
94. Lim, S.P.; Wang, Q.-Y.; Noble, C.G.; Chen, Y.-L.; Dong, H.; Zou, B.; Yokokawa, Y.; Nilar, S.; Smith, P.; Beer, D.; Lescar, J.; Shi, PY. Ten years of dengue drug discovery: Progress and prospects. Antiviral Res., 2013, 100, 500-519.
95. van Cleef, K.W.R.; Overheul, G.J.; Thomassen, M.C.; Kaptein, S.J.F.; Davidson, A.D.; Jacobs, M.; Neyts, J.; van Kuppeveld, F.J.M.; van Rij, R.P. Identification of a new dengue virus inhibitor that targets the viral NS4B protein and restricts genomic RNA replication. Antiviral. Res., 2013, 99, 165-171.
96. Miller, S.; Sparacio, S.; Bartenschlager, R. Subcellualr localization and membrane topology of the dengue virus type-2 non structural protein 4B. J. Biol. Chem., 2006, 281, 8884-8863.
97. Nemésio, H.; Palomares-Jerez, F.; Villalaín, J. NS4A and NS4B proteins from dengue virus: Membranotropic regions. Biochim. Biophys. Acta, 2012, 1818, 2818-2830.
98. Rathore, A.P.S.; Ng, M.L.; Vasudevan, S.G. Differential unfolded protein response during chikungunya and sindbis virus infection: CHIKV nsP4 suppresses eIF2α phosphorylation. Virol. J., 2013, 10, 36.
99. Tomar, S.; Hardy, R.W.; Smith, J.L.; Kuhn, R.J. Catalytic core of alphavirus nonstructural protein nsP4 possesses terminal adenylyltransferase activity. J. Virol., 2006, 80, 9962.
100. Strauss, J.H.; Strauss E.G. The alphaviruses: gene expression, replication, and evolution. Microbiol. Rev., 1994, 58, 491.
101. Sreejith, R.; Rana, J.; Dudha, N.; Kumar, K.; Gabrani, R.; Sharma, S.K.; Gupta, A.; Vrati, S.; Chaudhary, V.K.; Gupta, S. Mapping interactions of Chikungunya virus nonstructural proteins. Virus Res., 2012, 169, 231-236.
102. Lipinski, C.A.; Lombardo, F.; Dominy, B.W.; Feeney, P.J. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Deliv. Rev., 1997, 23, 3-25.